TB-500 is the synthetic research fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide present in nearly every human cell. Unlike BPC-157's gastric origin, Thymosin Beta-4's native role is as an actin-regulating protein — and that mechanism is what the tendon, muscle, and cardiac repair literature keeps coming back to.
What Is TB-500?
TB-500 refers to the synthetic version of the biologically active region of Thymosin Beta-4 (Tβ4), a peptide first isolated from thymus tissue and now known to be expressed across most cell types, particularly at sites of tissue injury. It is not a novel discovery so much as a synthesized fragment of a protein the body already produces and upregulates during wound repair.
Mechanism of Action
Thymosin Beta-4's core, most-replicated mechanism is actin regulation: it binds monomeric G-actin and prevents its polymerization into filaments, which governs cell migration, lamellipodia formation, and cytokinesis. Because nearly every form of tissue repair depends on cells migrating into the injury site, this single mechanism plausibly explains its broad footprint across tendon, muscle, skin, and cardiac research.
- Actin-binding — regulates the cytoskeletal dynamics that drive cell migration into injured tissue
- VEGF and angiopoietin-1 induction — promotes angiogenesis, new blood vessel formation to meet healing tissue's metabolic demand
- NF-κB downregulation — a proposed anti-inflammatory pathway relevant to chronic joint and soft-tissue injury
- Akt/mTOR activation — linked to cell survival and reduced apoptosis in injured tissue
What the Preclinical Research Shows
As with most peptides in this category, the evidence base is preclinical — animal and cell-culture models, not human trials. By tissue type:
- Muscle — a directly cited mechanism: muscle-injury-induced Thymosin Beta-4 acts as a chemoattractant for myoblasts, drawing muscle precursor cells to the injury site
- Tendon & ligament — accelerated cell migration and wound closure attributed to the same actin-regulation mechanism, alongside reduced scar-tissue formation in animal models
- Cardiac — the deepest literature outside of tendon/muscle: reduced infarct size and preserved cardiac function after coronary artery ligation in mouse models, via a proposed two-phase mechanism — an acute anti-apoptotic/anti-inflammatory phase, followed by a chronic phase activating vascular and cardiac progenitor cell growth
- Skin / wound healing — accelerated closure attributed to the same angiogenesis and cell-migration pathways studied in tendon and cardiac models
All cardiac findings above come from ischemic-injury animal models (primarily mouse), not human cardiology research. TB-500 is not a treatment for cardiovascular disease and none of this literature should be read as clinical evidence.
Regulatory & Safety Status
TB-500 was one of seven peptides FDA's Pharmacy Compounding Advisory Committee (PCAC) formally reviewed on July 23–24, 2026 for possible addition to the Section 503A Bulk Drug Substances List — the same meeting that reviewed BPC-157 (see our BPC-157 guide for the fuller regulatory background). FDA's own scientific staff recommended against adding any of the seven peptides under review, citing insufficient safety and efficacy evidence. The committee voted narrowly to recommend TB-500 anyway, one of six peptides (of seven reviewed) the panel backed — only Emideltide was voted down.
This is a non-binding recommendation, not a rule change or an approval. FDA is not required to follow PCAC's vote. If FDA moves forward, it happens through formal rulemaking that could take until 2027 or 2028 — this is not something that makes TB-500 legally compoundable today. As of this writing, TB-500 remains not FDA-approved for any human use, and nothing about its actual legal status has changed as a result of this vote.
Separately from the bulk-substance list question, selling an unapproved drug for human use can implicate misbranding and adulteration law regardless of Category 2/503A status — the same caveat that applies to every research peptide discussed on this site.
FDA rulemaking and advisory outcomes change over time — this status was verified against FDA and news reporting as of 2026-07-31. If you're making a decision based on current regulatory status, re-verify it directly rather than relying on this page's snapshot.
Where to Source TB-500 for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the TB-500 product page →Frequently Asked Questions
Is TB-500 the same thing as Thymosin Beta-4?
TB-500 is a synthetic version of a biologically active fragment of Thymosin Beta-4 (Tβ4). The names are often used interchangeably in the research-peptide market, but TB-500 specifically refers to the synthesized research compound, not the full native protein.
Is TB-500 approved by the FDA for human use?
No. On July 23, 2026, an FDA advisory committee voted to recommend adding TB-500 to the list of substances compounding pharmacies can legally prepare, over FDA staff's own objection that the evidence doesn't support it. That's a non-binding recommendation, not an approval; formal FDA rulemaking, if it happens, could take until 2027 or 2028. TB-500 remains not FDA-approved for any human use today.
Why is TB-500 often paired with BPC-157?
The two compounds are frequently studied together because their proposed mechanisms are complementary rather than redundant — BPC-157's evidence base centers on angiogenesis and gut-mucosal repair via VEGFR2/Akt-eNOS signaling, while TB-500's centers on actin-mediated cell migration. Aura's Wolverine Stack pairs the two for exactly this reason.
Does the cardiac research mean TB-500 has cardiovascular applications?
No — the cardiac literature is entirely preclinical, ischemic-injury animal models. It's relevant to researchers studying cardiac repair mechanisms, not evidence of any human cardiovascular benefit.
References
1. "Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review." MDPI Applied Sciences
2. "Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts." PubMed
3. "Cardioprotection by Thymosin Beta 4." PubMed
4. "Thymosin beta4 is cardioprotective after myocardial infarction." PubMed
5. "Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury." PMC
6. "Thymosin β4 and cardiac regeneration: are we missing a beat?" PubMed
7. Stone W. "FDA panel supports broadening access to peptides popular on the gray market." NPR, July 23–24, 2026. npr.org
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.